105 related articles for article (PubMed ID: 8735680)
1. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
Shyu WC; Morgenthien EA; Barbhaiya RH
Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
[TBL] [Abstract][Full Text] [Related]
2. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans.
Vachharajani NN; Shyu WC; Greene DS; Barbhaiya RH
Biopharm Drug Dispos; 1997 Apr; 18(3):191-202. PubMed ID: 9113342
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.
Davis GA; Rudy AC; Archer SM; Wermeling DP
Am J Health Syst Pharm; 2004 Feb; 61(3):261-6. PubMed ID: 14986556
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps.
Wermeling DP; Miller JL; Archer SM; Rayens MK; Rudy AC
J Clin Pharmacol; 2005 Aug; 45(8):969-73. PubMed ID: 16027409
[No Abstract] [Full Text] [Related]
6. Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women.
Vachharajani NN; Shyu WC; Barbhaiya RH
J Clin Pharmacol; 1997 Oct; 37(10):979-85. PubMed ID: 9505990
[TBL] [Abstract][Full Text] [Related]
7. Multiple-dose phase I study of transnasal butorphanol.
Shyu WC; Pittman KA; Robinson D; Barbhaiya RH
Clin Pharmacol Ther; 1993 Jul; 54(1):34-41. PubMed ID: 8330463
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate.
Srinivas NR; Shyu WC; Upmalis D; Lee JS; Barbhaiya RH
J Clin Pharmacol; 1995 Apr; 35(4):432-7. PubMed ID: 7650235
[TBL] [Abstract][Full Text] [Related]
9. The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol.
Shyu WC; Morgenthien EA; Pittman KA; Barbhaiya RH
Eur J Clin Pharmacol; 1994; 47(1):57-60. PubMed ID: 7988625
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
11. The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis.
Shyu WC; Pittman KA; Robinson DS; Barbhaiya RH
Eur J Clin Pharmacol; 1993; 45(6):559-62. PubMed ID: 8157043
[TBL] [Abstract][Full Text] [Related]
12. Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine.
Shyu WC; Barbhaiya RH
Br J Clin Pharmacol; 1996 Oct; 42(4):513-7. PubMed ID: 8904627
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration.
Wells SM; Glerum LE; Papich MG
Am J Vet Res; 2008 Dec; 69(12):1548-54. PubMed ID: 19045999
[TBL] [Abstract][Full Text] [Related]
14. Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol.
Shyu WC; Mayol RF; Pfeffer M; Pittman KA; Gammans RE; Barbhaiya RH
Biopharm Drug Dispos; 1993 Jul; 14(5):371-9. PubMed ID: 8218955
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses.
Chiavaccini L; Claude AK; Lee JH; Ross MK; Meyer RE; Langston VC
J Vet Pharmacol Ther; 2015 Aug; 38(4):365-74. PubMed ID: 25484250
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Riggs SM; Hawkins MG; Craigmill AL; Kass PH; Stanley SD; Taylor IT
Am J Vet Res; 2008 May; 69(5):596-603. PubMed ID: 18447789
[TBL] [Abstract][Full Text] [Related]
17. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Layton G; Leclerc V; Weil A
Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of butorphanol after intravenous, intramuscular, and oral administration in Hispaniolan Amazon parrots (Amazona ventralis).
Guzman DS; Flammer K; Paul-Murphy JR; Barker SA; Tully TN
J Avian Med Surg; 2011 Sep; 25(3):185-91. PubMed ID: 22216718
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus).
Tana LM; Isaza R; Koch DE; Hunter RP
J Zoo Wildl Med; 2010 Sep; 41(3):418-25. PubMed ID: 20945638
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs.
Troncy E; Besner JG; Charbonneau R; Cuvelliez SG; Blais D
J Vet Pharmacol Ther; 1996 Aug; 19(4):268-73. PubMed ID: 8866454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
